{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:06:54Z","timestamp":1790982414002,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cmi.2019.05.012","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T09:48:16Z","timestamp":1558604896000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections"],"prefix":"10.1016","volume":"26","author":[{"given":"M.N.","family":"Al-Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.05.012_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1469-0691.12195","article-title":"Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe","volume":"19","author":"Goto","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/AAC.00462-11","article-title":"Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis","volume":"56","author":"Retamar","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.012_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/dkw402","article-title":"Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis","volume":"72","author":"Battle","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.012_bib4","first-page":"28","article-title":"Recurrent Gram-negative bloodstream infection: a 10-year population-based cohort study","volume":"61","author":"Al-Hasan","year":"2010","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/cit499","article-title":"Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia","volume":"57","author":"L\u00f3pez-Cort\u00e9s","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jamainternmed.2017.3958","article-title":"Association of evidence-based care processes with mortality in Staphylococcus aureus bacteremia at veterans health administration hospitals, 2003\u20132014","volume":"177","author":"Goto","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2019.05.012_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cmi.2015.05.013","article-title":"Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization","volume":"21","author":"Brigmon","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjmed.2012.04.010","article-title":"Bloodstream infection, venous thrombosis, and peripherally inserted central catheters: reappraising the evidence","volume":"125","author":"Chopra","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.05.012_bib12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","article-title":"Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection","volume":"117","author":"Markowitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.012_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jac\/dky452","article-title":"Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer","volume":"74","author":"Jorgensen","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.012_bib16","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","author":"Willekens","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207413","article-title":"Intravenous to oral switch therapy in cancer patients with catheter-related bloodstream infection due to methicillin-sensitive Staphylococcus aureus: a single-center retrospective observational study","volume":"13","author":"Itoh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2019.05.012_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s13063-015-0973-x","article-title":"Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial","volume":"16","author":"Kaasch","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.cmi.2019.05.012_bib19","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1093\/ofid\/ofy210.838","article-title":"Evaluation of the clinical efficacy and safety of oral antibiotic therapy for Streptococcus spp. bloodstream infections","volume":"5","author":"Kang","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(89)91083-0","article-title":"Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin","volume":"2","author":"Dworkin","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2019.05.012_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cmi.2016.04.003","article-title":"Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients","volume":"22","author":"Mzabi","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.05.012_bib25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A\u00a0randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2019.05.012_bib27","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0025-6196(11)62596-2","article-title":"Linezolid therapy for orthopedic infections","volume":"79","author":"Razonable","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2019.05.012_bib29","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1093\/ofid\/ofy210.317","article-title":"Safety and tolerability of tedizolid as oral treatment for bone and joint infections","volume":"5","author":"Launer","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib30","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/0002-9343(89)90055-7","article-title":"Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections","volume":"87","author":"Peacock","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/106002809603000605","article-title":"Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis","volume":"30","author":"Amodio-Groton","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2019.05.012_bib32","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-014-3233-0","article-title":"Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia","volume":"59","author":"Park","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2019.05.012_bib33","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/phar.2024","article-title":"Intravenous-only or intravenous transitioned to oral antimicrobials for Enterobacteriaceae-associated bacteremic urinary tract infection","volume":"37","author":"Rieger","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.05.012_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib35","series-title":"Definitive intravenous antibiotics versus oral ciprofloxacin in patients with monomicrobial Gram-negative bacteremia","author":"Cook","year":"2018"},{"key":"10.1016\/j.cmi.2019.05.012_bib36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2016.07.013","article-title":"Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections","volume":"48","author":"Kutob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.05.012_bib37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijantimicag.2017.12.007","article-title":"Retrospective analysis comparing oral stepdown therapy for Enterobacteriaceae bloodstream infections: fluoroquinolones versus \u03b2-lactams","volume":"51","author":"Mercuro","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.05.012_bib38","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1093\/ofid\/ofy210.909","article-title":"Streamlining to oral \u03b2-lactam vs. fluoroquinolone as definitive therapy for Enterobacteriaceae bacteremia","volume":"5","author":"Fong","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib39","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1093\/ofid\/ofy210.874","article-title":"Effect of oral step-down therapy on readmission rates in Escherichia coli bacteremia","volume":"5","author":"Sessa","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib40","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1128\/AAC.02728-15","article-title":"Prediction of fluoroquinolone resistance in Gram-negative bacteria causing bloodstream infections","volume":"60","author":"Dan","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.012_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01166-17","article-title":"Use of the Accelerate Pheno System for identification and antimicrobial susceptibility testing of pathogens in positive blood cultures and impact on time to results and workflow","volume":"56","author":"Charnot-Katsikas","year":"2018","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.05.012_bib42","series-title":"Empirical fluoroquinolone vs. \u03b2-lactam monotherapy for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors","author":"Gould","year":"2018"},{"key":"10.1016\/j.cmi.2019.05.012_bib43","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1469-0691.12607","article-title":"External validation of Gram-negative bloodstream infection mortality risk score in a population-based cohort","volume":"20","author":"Al-Hasan","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cmi.2019.05.017","article-title":"Evaluation of early clinical failure criteria for Gram-negative bloodstream infections","volume":"26","author":"Rac","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","volume":"23","author":"Harris","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib46","first-page":"266","article-title":"Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis","volume":"82","author":"Greenberg","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib47","first-page":"262","article-title":"Clinical efficacy of ciprofloxacin therapy for Gram-negative bacillary osteomyelitis","volume":"82","author":"Hessen","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib48","first-page":"254","article-title":"Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic Gram-negative bacilli","volume":"82","author":"Gilbert","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib49","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMcp0910753","article-title":"Clinical practice: vertebral osteomyelitis","volume":"362","author":"Zimmerli","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0002-9343(78)90821-5","article-title":"Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole","volume":"65","author":"Galgiani","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0016-5085(82)80085-1","article-title":"Peptococcus asaccharolyticus bacteremia with liver involvement cured with oral metronidazole","volume":"83","author":"Watanakunakorn","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2019.05.012_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.1979.03630390027013","article-title":"Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess","volume":"139","author":"Warner","year":"1979","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib53","first-page":"170","article-title":"Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA study)","volume":"21","author":"Weiss","year":"2009","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2019.05.012_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.012_bib55","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.012_bib56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib57","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib58","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2334-14-97","article-title":"Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial","volume":"14","author":"Vazquez","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2334-13-219","article-title":"Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label phase III trial","volume":"13","author":"Mootsikapun","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/myc.12094","article-title":"An open-label study of anidulafungin for the treatment of candidaemia\/invasive candidiasis in Latin America","volume":"57","author":"Nucci","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.012_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijcp.12231","article-title":"Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience","volume":"68","author":"Bal","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cmi.2019.05.012_bib63","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial","author":"Kullberg","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib64","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MD.0b013e3182259d38","article-title":"The role of fluconazole in the treatment of candida endocarditis: a meta-analysis","volume":"90","author":"Smego","year":"2011","journal-title":"Medicine (Balt)"},{"key":"10.1016\/j.cmi.2019.05.012_bib65","first-page":"829","article-title":"Fluconazole level in aqueous humor after oral drug administration in humans","volume":"92","author":"Aust","year":"1995","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.cmi.2019.05.012_bib66","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.suc.2014.08.003","article-title":"Bloodstream infections and central line-associated bloodstream infections","volume":"94","author":"Watson","year":"2014","journal-title":"Sur Clin N Am"},{"key":"10.1016\/j.cmi.2019.05.012_bib67","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.05.012_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1017\/ice.2018.10","article-title":"Electronically available comorbid conditions for risk prediction of healthcare-associated Clostridium difficile infection","volume":"39","author":"Harris","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2019.05.012_bib69","article-title":"Role of early de-escalation of antimicrobial therapy on risk of Clostridioides difficile infection following Enterobacteriaceae bloodstream infections","author":"Seddon","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib70","series-title":"Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics","year":"2019"},{"key":"10.1016\/j.cmi.2019.05.012_bib71","series-title":"FDA updates warnings for fluoroquinolone antibiotics","year":"2016"},{"key":"10.1016\/j.cmi.2019.05.012_bib72","series-title":"Fluoroquinolone antibiotics safety communication: increased risk of ruptures or tears in the aorta blood vessel in certain patients","year":"2018"},{"key":"10.1016\/j.cmi.2019.05.012_bib73","series-title":"FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes","year":"2018"},{"key":"10.1016\/j.cmi.2019.05.012_bib74","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2018.13155","article-title":"Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia: a randomized clinical trial","volume":"320","author":"Holland","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.05.012_bib75","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/1471-2334-13-365","article-title":"Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case\u2013control study","volume":"13","author":"Kang","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.012_bib76","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/cid\/cix648","article-title":"Follow-up blood cultures in Gram-negative bacteremia: are they needed?","volume":"65","author":"Canzoneri","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19302277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19302277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:23:34Z","timestamp":1761117814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19302277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1198743X19302277"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.05.012","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}